11C-methionine PET as a prognostic marker in patients with glioma:: comparison with 18F-FDG PET
11C-methionine PET as a prognostic marker in patients with glioma:: comparison with 18F-FDG PET
复制标题
DOI：
10.1007/s00259-004-1598-6
复制
发表时间：
2005-01-01
影响因子：
9.1
通讯作者：
Lee, MC
中科院分区：
文献类型：
--
作者：
Kim, S;Chung, JK;Lee, MC
目的：本研究旨在比较C - 11 - 蛋氨酸（MET）和F - 18 - 氟脱氧葡萄糖（FDG）正电子发射断层扫描（PET）在胶质瘤患者中的预后价值。
方法：研究对象包括47例胶质瘤患者（19例胶质母细胞瘤，28例其他类型）。所有患者在2周的时间间隔内进行了治疗前磁共振成像、MET PET和FDG PET检查。计算了摄取率和标准摄取值。进行了单变量和多变量分析以确定重要的预后因素。通过免疫组织化学染色测量Ki - 67指数，并与胶质瘤中FDG和MET的摄取情况进行比较。
结果：在若干临床病理预后因素中，肿瘤病理类型（是否为胶质母细胞瘤）、年龄（≥60岁或＜60岁）……
Purpose: The purpose of this study was to compare the prognostic value of C-11-methionine (MET) and F-18-fluorodeoxyglucose (FDG) positron emission tomography (PET) in glioma patients.Methods: The study population comprised 47 patients with gliomas (19 glioblastoma, 28 others). Pretreatment magnetic resonance imaging, MET PET and FDG PET were performed within a time interval of 2 weeks in all patients. The uptake ratio and standard uptake values were calculated. Univariate and multivariate analyses were done to determine significant prognostic factors. Ki-67 index was measured by immunohistochemical staining, and compared with FDG and MET uptake in glioma.Results: Among the several clinicopathological prognostic factors, tumour pathology (glioblastoma or not), age (greater than or equal to60 or